Doesn’t take a genius to figure out that price manipulation over time without the right kind of news was going to continue no matter what they did. Hiring someone to give the appearance that uplisting might take place soon was likely the impetus but the reality was/is that even a reverse split would come under attack without sufficient news ie finalized and digitized Flaskworks production model that allows reimbursement models to work. This is especially true where off label process use due to biomarker identification from proteomics might lead to more rapid label extensions for approval. Initial testing of artisan method digitization during ramp up will be a good way to test for any oversight issues. Franchise modeling with Flaskworks seems likely and digitization with assigned tracking codes likely sends all info simultaneously for tracking similar to how packages are tracked. Best wishes.
Market Data 
Markets 
AI
